glp-1 and libido does semaglutide increase sex drive GLP-1's have been a powerful tool for obesity diabetes GLP-1 Medications Infographic | Medidex

A small number of users may experience gastrointestinal effects so severe that they need to stop taking the medication

We are social creatures and creating habits that involve with being with other people

If a substance is not approved for clinical use by any governmental regulatory authority and has performance enhancing potential, it may be prohibited under the S0 category

Expression of glucose transporter isoform GLUT-2 and glucokinase genes in human brain

Other common symptoms like semaglutide-related burping , dizziness , and tirzepatide-related diarrhea typically resolve within a few weeks of dose stabilization

Biased Agonism: Does It Work?# The Evidence So Far# Two drugs in this comparison -- ecnoglutide and CT-388 -- were specifically engineered with biased agonism to improve tolerability: Ecnoglutide (cAMP-biased at GLP-1R): Discontinuation due to AEs: approximately 2%, among the lowest reported for any GLP-1 agonist Weight loss of 13.2% at 40 weeks is competitive with semaglutide-class efficacy The tolerability-to-efficacy ratio appears favorable CT-388 (signal-biased at both GLP-1R and GIPR): Despite very high Phase 1b GI rates during titration (83% nausea), Phase 2 showed only 5.9% AE discontinuation Weight loss of 22.5% at 48 weeks is among the highest in the field The tolerability-to-efficacy ratio is notable: comparable weight loss to tirzepatide with a lower discontinuation rate What the Data Suggest# The biased agonism hypothesis appears to be supported by early clinical data, though with important caveats: Biased agonists do not eliminate GI side effects -- they may reduce their severity and duration The key metric is discontinuation, not incidence -- a drug with high nausea rates but low discontinuation may indicate transient, manageable symptoms Longer and larger trials are needed -- both ecnoglutide and CT-388 have limited Phase 3 data available Patterns and Insights# More Receptors, More Side Effects# A general pattern emerges: adding receptor targets increases both efficacy and GI side effect burden